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EFFECTIVENESS AND COST-BENEFIT OF A BUPIVACAINE PHYSICIAN
EDUCATIONAL PROGRAMME IN MINIMIZING THE SPINAL ANESTHESIA
FAILURE RATE: REPORT FROM A TERTIARY-CARE HOSPITAL IN CENTRAL
TAIWAN
Hsu HM1, Chang SHC1, Huang YC1, Chen KB2
1AstraZeneca Taiwan, Taipei, Taiwan, 2Department of Anesthesiology, Taichung, Taiwan
OBJECTIVES:To evaluate the effectiveness, aswell as the cost-benefit of a hospital-
wide physician educational programme in minimizing the spinal anesthesia (SA)
failure rate.METHODS: A bupivacaine physician educational programme was ini-
tiated in June 2011 tominimize the SA failure rate in the Anesthesia Department of
a tertiary-care hospital in Central Taiwan. We then used the patients recorded in
the institution who underwent SA from January 2010 through December 2011, to
evaluate the effectiveness aswell as the cost-benefit of the programme, taking into
consideration the cost of the training. To minimize potential impact of seasonal
change, we compare two patient cohorts, the pre-training and the post-training
cohorts, that were collected during July to December in 2010 and 2011, respectively.
Logistic regression model was used to evaluate how well the application of the
programme will predict SA failure rate, after controlling for potential impact of
seasonal change. From the payer’s perspective, the cost-benefit of the training was
evaluated by calculating the cost needed under the SA failure rates before and after
the training, based on the true number of patients undergoing SA after the training.
The approved payments from the Bureau of National Health Insurance were used
to do the calculation. RESULTS: There were 1841 and 2372 patients undergoing SA
in the pre-training and post-training periods, respectively. The SA failure rate re-
duced from2.66% to 1.39% in the twoperiods. The training is a predictor of lower SA
failure rate (OR 0.57; 95% CI 0.41-0.79, p0.001). A cost reduction of 3.13% was
noted, indicating the cost-benefit of the training. CONCLUSIONS: The physician
educational programme was associated with a significantly lower SA failure rate,
with a RRR of 43%. Moreover, it had a significant cost-benefit profile from the
payer’s perspective.
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FACTORS ASSOCIATED WITH PHYSICIAN PARTICIPATION IN A NATIONAL
CONTINUING MEDICAL EDUCATION PROGRAM
Lai CL1, Hou YH2, Chang RE1
1National Taiwan University, Taipei, Taiwan, 2Kainan University, Taoyuan, Taiwan
OBJECTIVES: To improve the quality of diabetes care and assist physicians in ac-
quiring the knowledge base and skills required for diabetes management, the dia-
betesmellitus pay-for-performance programwas integratedwith continuingmed-
ical education (CME) and implemented in 2001. Our study examined CME’s
prevalence among physicians and explored the factors associated with variations
in CME participation.METHODS: This cross-sectional comparison study analyzed
the National Health Insurance (NHI) claim data for the year 2008 obtained from the
National Health Research Institutes. Descriptive and multiple logistic regression
analyses were conducted to investigate the factors associated with differential
physician participation in CME. The factors considered included the characteristics
of the physician, the organization, and the regulatory body. RESULTS: A total of
43% of the NHI registry physicians in this study (n  18,284) had diabetes patients
in 2008, but only 7% were participating in DM-P4P. The factors significantly asso-
ciated with participation status were as follows: 1) the physician factor, including
gender, specialty, practice location, number of diabetes patients, and ratio of ma-
jority provider; 2) the organizational factor, including the practice setting and own-
ership; and 3) the regulatory factor, including the time period for implementing the
Diabetes Shared Care Program and the NHI’s regulatory districts. CONCLUSIONS:
This study revealed that under the same financial incentives, physicians had dif-
ferent degrees ofwillingness to participate in the CME,which could be attributed to
the physician, organizational, and regulatory factors. Most of the physicians treat-
ing diabetes in Taiwan were not endocrinologists and their expertise was widely
distributed among diverse specialties. The CME was a key component in develop-
ing physicians’ competencies and driving improvements on national diabetes care
quality; a low level of participationwould however hinder its effects. Policymakers
may need to consider various arrangements for increasing physician participation.
HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment
Programs
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NATIONAL HEALTH INSURANCE CLAIMS DATABASE AS A VALUABLE SOURCE
OF INFORMATION FOR HEALTH TECHNOLOGY ASSESSMENT IN TAIWAN
Wang YC, Pwu RF
Center for Drug Evaluation, Taipei, Taiwan
OBJECTIVES: Health Technology Assessment (HTA) is developed out of the best
scientific evidence in medical, organizational, social, ethical and economic aspect,
to provide decison makers as a decision aid. Health decison makers increasingly
seek information on real-world outcomes; one of such information sources is
administrative claims database. The aim of this study is to explore the types of
information that administrative claims database has been used in the assessment
reports made by Taiwanese HTA agency (CDE/HTA). METHODS: We collected all
the statistics used or analysis results estimated from health insurance database in
the assessment reports that CDE/HTA produced during 2008-2011. These results
were further classified by the indication of the product, type of statistics used, and
sections of the report. Descriptive analysis was performed. RESULTS: There were
34 assessment reports presented statistical data out of National Health Insurance
database in 2008-2011. These included 19 New Drug Applications, 13 Commis-
sioned Research and 2 Medical Device Review. For the types of indications, the
most frequently applied were the drugs used in the area of “the musculoskeletal
systemand connective tissue” and “the nervous systemand sense organs”(18%). Of
all the different types of database used, 65% used longitudinal health insurance
database. Mostly used statistics were “the number of patients using drug” (47%)
and “the number of patients with diagnosis” (38%). “Burden of disease” (47%) and
“budget impact” (32%) were the report sections that presented most of these data.
CONCLUSIONS: At present, most of the CDE/HTA assessments rely on the Longi-
tudinal Health Insurance Database for estimating “the number of patients with
diagnosis” or “the number of patients using drug”. This study has described the
extensively use of claims database in Taiwanese HTA reports. Further usage of
claimsdataset on cost effectiveness analysis or comparative effectiveness research
is expected.
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IDENTIFYING MODELING FACTORS INFLUENCING COVERAGE DECISIONS BY
NICE IN 10 SINGLE TECHNOLOGY APPRAISALS (STA) OF EXPENSIVE DRUGS
Nguyen H1, Wang BCM2, Garrison L3
1University of Washington, Seattle, WA, USA, 2Adjility Health, New York, NY, USA, 3University
of Washington, Seattle, WA, USA
OBJECTIVES: TheNational Institute for Health and Clinical Excellence (NICE) single
technology appraisal (STA) process was introduced in 2005 as a rapid way to ap-
praise new technologies for use within the NHS in England and Wales. Manufac-
turers are recommended to follow the NICE reference case in presenting clinical
effectiveness and cost-effectiveness evidence in their submissions to NICE. The
purpose of this research was to identify common modeling factors in the manu-
facturer submissions (MS) of expensive technologies that impacted NICE coverage
decisions. METHODS: An analysis of MS and Evidence Review Group reports was
undertaken for 10 technologies (2007-2011) with similar route of administration
and annual treatment cost. Datawas obtained from theNICEwebsite and extracted
on key elements of the strengths and weaknesses of the MS. All STAs were for
drugs with annual treatment costs  £8,000 per year and administered intrave-
nously by injection or infusion. All drug treatments were long-term and indicated
for a range of chronic diseases. RESULTS: Of the 10 STAs, 8 were recommended by
NICE; 4 of the 8 recommended technologies included patient access schemes (PAS).
The duration of the STAs ranged from approximately 36 to 129weeks. Delays in the
STA process were due to poor quality of submissions. Economic evaluations were
either cost-utility or cost-effectiveness analyses. Excel-based Markovmodels were
commonly used to simulate long-term processes.We identifiedmany variations in
the submittedmodels across different characteristics, including calculation of util-
ity values, choice of relevant model population, type of comparator, perspective
and time horizon, inclusion of sensitivity analyses, use of indirect comparison
methods, and availability of systematic literature review. CONCLUSIONS:MS that
were comprehensive, transparent, and internally consistent experience more effi-
cient STA process and positive appraisal outcomes. Manufacturers with expensive
drugs may consider including PAS in their economic evaluations as part of their
submission.
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THE INDUSTRY SURVEY RESULTS REGARDING KOREA PE GUIDELINE REVISION
Jung S1, KRPIA PE Working Group K2, KPMA PE Working Group K3
1Bayer Korea, Seoul, South Korea, 2Korea Research-based Pharmaceutical Industry Association,
Seoul, South Korea, 3Korea Pharmaceutical Manufacturers Association, Seoul, South Korea
As Drug Expenditure Rationalization Plan has been implemented in Korea in 2006,
pharmacoeconomics (PE) guidelinewas developed byHealth Insurance Review and
Assessment service (HIRA) to appraise the economic evaluation. Since the imple-
mentation of HIRA PE guideline, various necessities have arisen by the viewers on
how to practically interpret and use the guideline. OBJECTIVES: This survey was
conducted to consolidate opinions of KRPIA (Korean Research-based Pharmaceu-
tical Industry Association) and KPMA (Korea Pharmaceutical Manufacturers Asso-
ciation) on the main issues of the revision of HIRA PE guideline for new medicine.
METHODS: The survey protocol was developed based on the experience of new
drug listing by KRPIA and KPMA members and completed during May 2011 by
e-mails in writing. The key anticipated outcomes were which categories of the
guideline revision the member companies consider necessary RESULTS: Among
KRPIA and KPMA member companies, 19 companies had answered. 63% (n12) of
the subjects answered they could not select the analysis method between CEA and
CUA because HIRA does not appreciate their choices. Among 89% (n17) thosewho
selected to answer the questions regarding detailed guideline for utility study, 71%
(n12) responded they agree with the necessity of the guideline on the condition if
CUA is not applicable CEA could be appreciated. Meanwhile, 26% (n5) responded
they had investigated clinical specialist or patient groups to design and conduct
effectiveness or utility analysis and the most frequently used method was a ques-
tion survey followed by Delphi panel and focus interview. CONCLUSIONS: The
member companies have demands for the revision in the way of operating the
economic evaluation. The key demands are creation of the manual to be followed
for the conduct of economic evaluation study, flexibility of the operation in the
consideration of severity of the indication, efficient and transparent management
of the consultation.
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IMPLEMENTATION OF A FORMULARY MANAGEMENT PROGRAMME IN
SINGAPORE
Zhao YJ, Teng M, Khoo AL, Lim BP
National Healthcare Group, Singapore, Singapore
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OBJECTIVES: To develop best practices, tools, capacity and capability for an effec-
tive formulary management system for five public health care institutions in
Singapore. METHODS: A survey was conducted among formulary committee
members of the participating institutions as part of gap analysis. A cross-institu-
tion task force comprising decision makers, clinicians, pharmacists and health
technology assessment (HTA) researchers from participating institutions was
formed to recommend best practices for formulary submission, evidence review
and synthesis, pharmacoeconomic evaluation and criteria for decision making.
Endorsement fromparticipating institutions’ stakeholderswas obtained before the
implementation of this programme. RESULTS: The gap analysis highlighted three
key areas for improvement: 1) methodologies for evidence review and synthesis,
and pharmacoeconomic evaluation; 2) criteria for formulary decision making; and
3) capacity and capability building especially in pharmacoeconomics. A set of tools
that facilitate evidence review and synthesis including guidelines for pharmaco-
economic evaluation was developed with reference to published literatures and
international guidelines. Clinical need, safety, efficacy, cost-effectiveness, budget
impact and opinion from subject matter experts were deemed as important deci-
sion-making criteria. A decision-making form incorporating these criteria was cre-
ated to facilitate the consistency and transparency of the decisionmaking process.
Workshops focused on HTA were conducted to equip pharmacists supporting for-
mulary management for participating institutions the knowledge and skills to ap-
praise clinical and economic evidence. In addition, a team comprising personnel
trained in pharmacoeconomics was set up to provide support to institutions phar-
macists on the application of HTA via joint review on selected new drug
applications. CONCLUSIONS: Support from participating institutions formulary
committees and seniormanagement are keys for the successful implementation of
this programme. Moving forward, the challenge is to integrate the proposed
changes into current practice.
HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment
Guidelines
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HYPERTENSION CONTROL AND DOCTORS’ KNOWLEDGE, ATTITUDE AND
PRACTICES ON MALAYSIAN CLINICAL PRACTICE GUIDELINES ON
MANAGEMENT OF HYPERTENSION (CPG 2008) AT A TERTIARY HOSPITAL
Ahmad N1, Hassan Y2, Tangiisuran B3, Meng OL4, Aziz NA5, Ahmad FUD6
1Universiti Sains Malaysia, Pinang, Penang, Malaysia, 2Universiti Teknologi MARA, Puncak
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Hospital, Penang, P. Penang, Malaysia, 5Universiti Teknologi MARA, Shah Alam, Selongor,
Malaysia, 6Universiti Sains Malaysia, Pulau Pinang, Malaysia
OBJECTIVES: To evaluate doctors’ knowledge, attitude and practices on Malaysian
CPG 2008 along with factors predicting guidelines adherence and hypertension
control. METHODS: This was a co-relational study conducted at Hospital Pulau
Pinang, Malaysia. A total of 26 doctors were enrolled. Doctors’ knowledge and
attitude onCPG (2008)were evaluated through a valid and reliable questionnaire. In
order to evaluate doctors’ actual prescribing practices, prescriptions written by 26
enrolled doctors to 650 established hypertensive outpatients (25 prescriptions per
doctor) were noted on visit one. The noted prescriptions were classified either as
compliant or noncompliant to CPG (2008). Five hundred and twenty enrolled pa-
tients (20 patients per doctor) were followed for one more visit. Blood pressure
noted on visit 2 was related to the prescription written on visit one. SPSS 16 was
used for data analysis. RESULTS: Nineteen doctors (73.07%) had adequate knowl-
edge of CPG (2008). Doctors were highly positive towards CPG (2008) with mean
attitude score of 23.151.34 points on a 30 point scale. Statistically significant
correlation (rs0.635, p-value0.001) was observed between doctors’ knowledge
and practice scores. The majority (67.1%) patients received guidelines compliant
therapy. In multivariate analysis hypertension clinic (OR0.398, p-value0.008)
was the strong predictor of poor adherence with guidelines. On visit Two 51%
patients were at goal BP. In multivariate analysis, Angiotensin converting enzyme
inhibitors (OR2.100, p-value0.001) and guidelines adherence (OR1.745,
p-value0.022) were the strong predictors of hypertension control, while renal dis-
ease (OR0.283, p-value0.001), diabetes mellitus (OR0.598, p-value0.025) and
diabetic clinic (OR0.384, p-value0.024) were the strong predictors of poor control
of hypertension. CONCLUSIONS: An overall fair level of doctors’ knowledge, ad-
herence with guidelines and control of hypertension was observed. The gaps be-
tween what guidelines recommended and clinical practice was especially seen in
the pharmacotherapy of uncomplicated hypertension and hypertension with dia-
betes mellitus and renal disease.
PHP105
GUIDELINE IMPLEMENTATION IN LONG TERM ASTHMA MANAGEMENT: AN
AUDIT USING A MEDICATION ASSESSSMENT TOOL IN SELAYANG HOSPITAL
Shaharuddin S1, Che Hasan MH1, Hashim R2
1UiTM, Bandar Puncak Alam, Selangor, Malaysia, 2CUCMS Main Campus, Cyberjaya, Selangor,
Malaysia
OBJECTIVES: To assess the current practice for the management of long term
asthma inMalaysia and the prescribing pattern among asthmatic patients by using
medication assessment tools (MAT). The MAT was developed according to guide-
line used by the physicians in Selayang Hospital.METHODS: The development and
validation of asthma MAT had undergone a process that involved selection of
guideline on long termasthmamanagement in adults. The recommendationswere
focused on pharmacologic management. Updated version of GINA guidelines was
used as GINA guidelines is known to be used in the management of long term
asthmatic patients in Selayang Hospital. The MAT tool was then discussed and
validated together with practising pharmacist. Pilot sampling was done and data
was then collected from patient medical record in Selayang Hospital. These data
were then assessed using Microsoft Access and Microsoft Excel. RESULTS: The
result showed that level of adherence towards guidelines used was 86.3% for 73
asthmatic patients that were selected. If magnification was made, however, the
reduction of current medication dose had not been made after the symptoms of
asthma have been controlled and only 39.4% had their dose reduced according to
the guideline. CONCLUSIONS: The adherence of guidelines seem to be high, how-
ever, improvement needs to bemade in reducing the dose once patients’ asthmatic
symptoms have been resolved.
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DIFFUSION OF NON-GUIDELINE EXPERIENCE-BASED CHEMOTHERAPY CARE
Tien YY1, Brooks J1, Wright K1, Link B2, Chrischilles EA1
1University of Iowa, Iowa City, IA, USA, 2University of Iowa, Iowa City, IA, USA
Clinical guidelines recommend patients with Diffuse Large B-Cell Lymphoma (DL-
BCL) receive anthracycline-based chemotherapy (ABC) treatment. During the
1990s, however, about one- third of elderly DLBCL patients did not receive chemo-
therapy, potentially due to intolerance of toxicities associated with ABC. With the
addition of rituxmab in the late 1990s, it appears that physicians choose to use
non-guideline rituximab plus non-ABC chemotherapy for patients with low toxic-
ity tolerance. OBJECTIVES: This study assesses the diffusion of the use of non-
guideline chemotherapy treatment for elderly DLBCL patients and examines the
regional variation in diffusion.METHODS:A retrospective cohort consisting of 5839
Medicare beneficiaries diagnosed in 2000-2006 with primary DLBCL at age 66 or
older treated with any chemotherapy was selected from the 2007 Surveillance,
Epidemiology and End Results (SEER)-Medicare linked database. Patients were ex-
cluded if physician information was not available (N55). Patient chemotherapy
was categorized usingMedicare claimswithin fivemonths of diagnosis. Physicians
(N3,072) were included if they prescribed any chemotherapy to patients during
the initial treatment period. Descriptive analyses were used to characterize varia-
tion in chemotherapy treatment across the SEER registry regions. RESULTS: Phy-
sicians prescribed ABC chemotherapy to on average 81.2% of received chemother-
apy patients. A totla of 19.8% of physicians, however, prescribed rituximab plus
non-ABC chemotherapy to at least one patient. The percentage of physicians
whom used rituximab plus non-ABC chemotherapy increased from 1.4% in 2000 to
16.1% in 2006. Louisiana, Connecticut, and Seattle were the top three SEER regions
where over 23% of the physicians prescribed this alternative chemotherapy. In
Hawaii, New Mexico, and Iowa SEER regions less that 14% of physician used this
alternative chemotherapy. CONCLUSIONS: The percentage of physicians having
adopted rituximab plus non-ABC chemotherapy as the alternative treatment in-
creased over the years. Physicians’ adoption of non-guideline treatment varies
across regions.
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OBSERVATIONS OF HEPATOCELLULAR CARCINOMA (HCC) MANAGEMENT
PATTERNS FROM THE GLOBAL HCC BRIDGE STUDY: AN INTERIM ANALYSIS OF
HCC BURDEN OF ILLNESS IN THE ASIA-PACIFIC (AP) COHORT
Orsini LS1, Park JW2, Kudo M3, Chen PJ4, Chen M5
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OBJECTIVES: HCC has a substantial disease burden worldwide, especially in AP.
The global HCC BRIDGE study is the first global, large-scale, observational study to
document real-world treatment pattern and outcomes of HCC patients from diag-
nosis to death. METHODS: This longitudinal cohort study includes HCC patients
newly diagnosed between January 2005 and June 2011 and treated atmajormedical
centers, with data collected retrospectively and prospectively as recorded in pa-
tient charts. RESULTS: In the first interim analysis (July 2011), 8909 patients (mean
age, 54 years; 83% male) were enrolled in AP (China, n6295; Taiwan, n1183;
Korea, n1136; Japan, n295). The predominant risk factorwasHBV inChina (80%),
Taiwan (67%), and Korea (77%), and HCV in Japan (69%). The predominant BCLC
stage at diagnosiswas stage C in China (56%) andKorea (51%) and stageA in Taiwan
(55%) and Japan (47%). Variations were noted between China, Taiwan, Korea, and
Japan in first-recorded treatment with resection/transplant (31%, 51%, 23%, 14%),
TACE (53%, 27%, 55%, 24%), other locoregional therapy (9%, 18%, 8%, 52%), and
systemic therapy (2%, 3%, 11%, 13%). There also were variations in treatment ever
used with resection/transplant (34%, 53%, 29%, 16%), TACE (61%, 37%, 65%, 28%),
other locoregional therapy (17%, 30%, 17%, 64%), and systemic therapy (5%, 9%,
30%, 19%). Recorded treatment by line of therapy, BCLC and mUICC stage, and
country will be presented from the second interim analysis, which will include
17,000 patients. Actual practice and expected practice according to guidelineswill
be evaluated, including how access issues may affect treatment availability.
CONCLUSIONS: The global HCC BRIDGE study, which is the largest study of its kind
(in approximately 19,000 patients), provides valuable insights into global HCC dis-
ease characteristics and patient management. Although AP has the highest HCC
burden, practice approaches differ across the region.
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PATTERN OF ANTIBIOTICS USAGE IN MALAYSIAN HAJJ PILGRIM
Abd Aziz N1, Hassan Y1, Hashim H2, Malik Mansoor S3, Abd Shatar AK4
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OBJECTIVES: During hajj season, more than 2 million hajj pilgrims would be occu-
pying the holy land Makkah with area of 164,000 km2. On the observation many of
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